CYCURION, INC. (CYCU)
Cycurion: 1-for-8 Reverse Split Backed by Stronger Fundamentals
Cycurion: 1-for-8 Reverse Split Backed by Stronger Fundamentals
U.S. FDA Approves Revolution Medicines’ RASONQUE™ (daraxonrasib), the First Broad RAS-Targeted Medicine in Metastatic Pancreatic Cancer
U.S. FDA Approves Revolution Medicines’ RASONQUE™ (daraxonrasib), the First Broad RAS-Targeted Medicine in Metastatic Pancreatic Cancer
Sodexo completes a euro-denominated bond issuance of EUR 1,100,000,000
Sodexo réalise une émission obligataire d’un montant de 1 100 000 000 d’euros
Pinnacle Bancshares Declares $0.27 Per Share Quarterly Cash Dividend
DEADLINE APPROACHING: Berger Montague Advises Hub Group, Inc. (NASDAQ: HUBG) Investors to Inquire About a Securities Fraud Class Action by August 28, 2026
Somnigroup International Announces New President of Leggett & Platt